<DOC>
	<DOC>NCT00426920</DOC>
	<brief_summary>Evaluation of the pharmacokinetics and pharmacodynamics of different doses of spray-dried recombinant human insulin powder for inhalation administered via a dry powder uinhalation device compared with subcutaneously administered regular human insulin in healthy male volunteers under the conditions of a eugycemic clamp.</brief_summary>
	<brief_title>Investigating the Pharmacokinetics and Pharmacodynamics of Recombinant Human Insulin Administered by Dry Powder Inhaler</brief_title>
	<detailed_description>Explorative, single-center, randomized, open label, 4-way crossover study to evaluate the pharmacokinetics and pharmacodynamics of different doses of spray-dried recombinant human insulin powder for inhalation administered via a dry powder uinhalation device compared with subcutaneously administered regular human insulin in healthy male volunteers under the conditions of a eugycemic clamp.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>male non smoking for at least 12 months BMI equal to or less than 28 no clinically significant abnormalities FVC and FEV1 equal to or more than 80% willing to participate and to sign informed consent form positive results for insulin antibodies at screening history of substance abuse or dependency within last 5 years positive screening test for substance abuse positive blood test for HIV, hepatitis B or hepatitis C antibody fasting blood glucose of more than 126mg/dl any existing medical conditions which might interfere with absoprtion, distribution, metabolism or excretion of study medication history of bronchospastic disease(asthma), tachycardia, migraine headache, hypoglycemic episodes, jaundice, liver diseases, arterial hemorrhaging, severe hypertension or hypotension, cardiac abnormality, renal disease, allergies, unresolved psychiatric illness, druginduced myopathy or any other clinically significant abnormality has received investigational medications within 21 days prior to receiving the first dose of study medication has taken or used any prescription medications within 21 days prior to receiving the first dose of study medication has taken or used any OTC medications,vitamins or herbal and/or nutritional supplements within 10 days days prior to receiving the first dose of study medication health that may be adversely affected by procedures or medications used in the study unwillingness or inability to understand or to follow required study restrictions and procedures</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>inhaled</keyword>
	<keyword>recombinant human insulin</keyword>
</DOC>